Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ibuprofen NDA approval

This article was originally published in The Tan Sheet

Executive Summary

Banner Pharmacaps' 505(b)(2) application (NDA 21-472) for ibuprofen 200 mg softgels approved by FDA Oct. 18. Product carries same indication as Wyeth's Advil Liqui-Gels. Banner says 505(b)(2) filing was necessary because there is no approved OTC ibuprofen with same dosage form and same active ingredient that would have allowed an ANDA filing. Advil Liqui-Gels have the same pharmacokinetic profile but contain partially titrated potassium salt of ibuprofen. Banner's product uses the free acid form of ibuprofen - the same as that found in standard ibuprofen tablets, caplets - but offers a different delivery form. Banner plans to partner with other firms to bring newly approved version to market...
Advertisement

Related Content

Banner naproxen petition

Topics

Advertisement
UsernamePublicRestriction

Register

PS094697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel